



# GLAND PHARMA LIMITED

January 23, 2021

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

**Sub: Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2021**

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed copies of the newspaper advertisement pertaining to Unaudited Financial Results of the Company for the Quarter and Nine months ended December 31, 2020. The advertisements were published in English and Telugu newspapers.

Yours truly,

For Gland Pharma Limited

**Sampath Kumar Pallerlamudi**  
Company Secretary



## GLAND PHARMA LIMITED

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad - 500 043, Telangana.  
CIN: U24239TG1978PLC002276 Tel: +91 40 3051 0999  
Website: [www.glandpharma.com](http://www.glandpharma.com); email: [investors@glandpharma.com](mailto:investors@glandpharma.com)

### EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

(₹ in millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations	8,594.19	8,315.00	6,459.35	25,751.28	19,980.02	26,332.40
Profit before tax	2,732.38	2,926.29	2,071.50	9,858.67	7,313.54	9,928.66
Profit for the period/year	2,041.07	2,188.57	1,540.99	7,365.54	5,780.65	7,728.58
Total comprehensive income (after taxes)	2,048.93	2,178.83	1,535.87	7,353.36	5,746.60	7,676.38
Paid up equity share capital (Face value of ₹1 each)	163.28	154.95	154.95	163.28	154.95	154.95
Other equity						36,307.40
<b>Earnings per equity share (Face value of ₹1 each):</b> (Not annualised for the quarter and nine months ended)						
Basic (₹)	12.83	14.12	9.95	47.12	37.31	49.88
Diluted (₹)	12.82	14.12	9.95	47.10	37.31	49.88

#### Notes:

- The Unaudited Financial Results for the quarter and nine months ended December 31, 2020 ("Unaudited Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 22, 2021 and have been subject to a limited review by the statutory auditors of the Company.
- The public issue net proceeds in the recently concluded Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended December 31, 2020.
- The above is an extract of the detailed format of Statement of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Financial Results are available on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) and on the website of the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and BSE Limited ([www.bseindia.com](http://www.bseindia.com)).

For and on behalf of the Board  
**Gland Pharma Limited**  
Sd/-  
**Srinivas Sadu**  
Managing Director and CEO  
DIN No. 06900659

Hyderabad  
January 22, 2021



## GLAND PHARMA LIMITED

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad – 500 043, Telangana.  
CIN: U24239TG1978PLC002276 Tel: +91 40 3051 0999  
Website: [www.glandpharma.com](http://www.glandpharma.com); email: [investors@glandpharma.com](mailto:investors@glandpharma.com)

### EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

(₹ in millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations	8,594.19	8,315.00	6,459.35	25,751.28	19,980.02	26,332.40
Profit before tax	2,732.38	2,926.29	2,071.50	9,858.67	7,313.54	9,928.66
Profit for the period/year	2,041.07	2,188.57	1,540.99	7,365.54	5,780.65	7,728.58
Total comprehensive income (after taxes)	2,048.93	2,178.83	1,535.87	7,353.36	5,746.60	7,676.38
Paid up equity share capital (Face value of ₹1 each)	163.28	154.95	154.95	163.28	154.95	154.95
Other equity						36,307.40
<b>Earnings per equity share</b> <b>(Face value of ₹1 each): (Not annualised for the quarter and nine months ended)</b>						
Basic (₹)	12.83	14.12	9.95	47.12	37.31	49.88
Diluted (₹)	12.82	14.12	9.95	47.10	37.31	49.88

#### Notes:

- The Unaudited Financial Results for the quarter and nine months ended December 31, 2020 ("Unaudited Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 22, 2021 and have been subject to a limited review by the statutory auditors of the Company.
- The public issue net proceeds in the recently concluded Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended December 31, 2020.
- The above is an extract of the detailed format of Statement of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Financial Results are available on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) and on the website of the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and BSE Limited ([www.bseindia.com](http://www.bseindia.com)).

For and on behalf of the Board  
Gland Pharma Limited

Sd/-

Srinivas Sadu  
Managing Director and CEO

DIN No. 06900659

Hyderabad  
January 22, 2021



# GLAND PHARMA LIMITED

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad – 500 043, Telangana.  
 CIN: U24239TG1978PLC002276 Tel: +91 40 3051 0999  
 Website: [www.glandpharma.com](http://www.glandpharma.com); email: [investors@glandpharma.com](mailto:investors@glandpharma.com)

## 31 డిసెంబరు, 2020తో ముగిసిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు ఆడిట్ చేయని ఆర్థిక ఫలితాల యొక్క సారాంశం

(₹ మిలియన్లలో)

వివరములు	ముగిసిన త్రైమాసికం			ముగిసిన తొమ్మిది నెలలు		ముగిసిన సంవత్సరం
	31-డిసెంబరు-20	30-సెప్టెంబరు-20	31-డిసెంబరు-19	31-డిసెంబరు-20	31-డిసెంబరు-19	31-మార్చి-20
	(ఆడిట్ చేయనివి)	(ఆడిట్ చేయనివి)	(ఆడిట్ చేయనివి)	(ఆడిట్ చేయనివి)	(ఆడిట్ చేయనివి)	(ఆడిట్ చేయనివి)
కార్యకలాపాల మండి ఆదాయం	8,594.19	8,315.00	6,459.35	25,751.28	19,980.02	26,332.40
పన్నుకుముందు లాభం	2,732.38	2,926.29	2,071.50	9,858.67	7,313.54	9,928.66
కాలం / సంవత్సరం కొరకు లాభం	2,041.07	2,188.57	1,540.99	7,365.54	5,780.65	7,728.58
మొత్తం సమగ్ర ఆదాయం (పన్నుల తరువాత)	2,048.93	2,178.83	1,535.87	7,353.36	5,746.60	7,676.38
చెల్లించిన ఈక్విటీ వాటా మూలధనం (ముఖ విలువ ₹ 1/- చొప్పున)	163.28	154.95	154.95	163.28	154.95	154.95
ఇతర ఈక్విటీ						36,307.40
ప్రతి వాటా ఆర్జనలు (ముఖ విలువ ₹ 1/- చొప్పున) (ముగిసిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు వార్షికరణం చేయబడినవి)						
బేసిక్ (₹)	12.83	14.12	9.95	47.12	37.31	49.88
డైల్యూటెడ్ (₹)	12.82	14.12	9.95	47.10	37.31	49.88

**గమనిక:**

- కంపెనీ ("ఆడిట్ చేయని ఆర్థిక ఫలితాలు") యొక్క డిసెంబరు 31, 2020తో ముగిసిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు ఆడిట్ చేయని ఆర్థిక ఫలితాలు ఆడిట్ కమిటీచే సమీక్షించబడినవి మరియు జనవరి 22, 2021న జరిగిన వారి సమావేశం వద్ద డైరెక్టర్ల బోర్డుచే అమోదించబడినవి మరియు కంపెనీ యొక్క సంస్థాగత ఆడిటర్లచే పరిమిత సమీక్షకు లోబడి ఉన్నవి.
- కంపెనీ యొక్క ప్రొసెక్యూటర్లలో తెలిపిన లక్ష్యాల ప్రకారం ఇటీవలి ముగిసిన ఆవిష్కరణల పట్ల ఆఫీసులో పట్లక ఇష్యూ నెట్ ప్రక్రియలు ఉపయోగించబడినవి. తదనుగుణంగా డిసెంబరు 31, 2020తో ముగిసిన త్రైమాసికం కొరకు పట్లక ఇష్యూ ప్రొసెక్యూటర్ల యొక్క వినియోగించుటలో ఏవేని దీనియేషన్లు లేదా వ్యత్యాసాలు మేము తెలుపవలసిన అవసరం లేదు.
- నెట్ (లిస్టింగ్ అడ్జస్ట్) మరియు డిస్కోంజర్ అవశ్యకతలు) రెగ్యులేషన్స్, 2015 యొక్క రెగ్యులేషన్ 33 క్రింద స్టాక్ ఎక్స్చేంజ్లతో దాఖలు చేయబడిన ఆర్థిక ఫలితాల యొక్క స్టేట్మెంట్ యొక్క సవరణ సమాచారం యొక్క సారాంశం పైన ఇవ్వబడినది. ఆర్థిక ఫలితాల యొక్క స్టేట్మెంట్ యొక్క పూర్తి సమాచారం కంపెనీ యొక్క వెబ్సైట్ ([www.gland-pharma.com](http://www.gland-pharma.com)) మరియు వేషనల్ స్టాక్ ఎక్స్చేంజ్ ఆఫ్ ఇండియా లిమిటెడ్ యొక్క వెబ్సైట్ ([www.nseindia.com](http://www.nseindia.com)) మరియు బిఎస్ఇ లిమిటెడ్ ([www.bseindia.com](http://www.bseindia.com)) పై కూడా పొందవచ్చును.

For and on behalf of the Board  
**Gland Pharma Limited**  
 Sd/-  
**Srinivas Sadu**  
 Managing Director and CEO  
 DIN No. 06900659

Hyderabad  
 January 22, 2021